Volume 12, Number 9—September 2006
Multidrug-resistant Tuberculosis Management in Resource-limited Settings
|Cure||Completed treatment according to country protocol and been consistently culture-negative (>5 results) for final 12 mo of treatment. If only 1 positive culture is reported during that time with no concomitant clinical evidence of deterioration, patient may still be considered cured, provided that positive culture is followed by >3 consecutive negative cultures taken >30 d apart.|
|Treatment completed||Completed treatment according to country protocol but does not meet definition for cure or treatment failure because of lack of bacteriologic results (i.e., <5 cultures were performed in the final 12 mo of therapy).|
|Death||Died for any reason during the course of MDRTB treatment.|
|Treatment default||Treatment was interrupted for >2 consecutive months for any reason.|
|Treatment failure||>2 of 5 cultures recorded in the final 12 mo are positive or if any of the final 3 cultures is positive. Treatment will also be considered to have failed if a clinical decision has been made to terminate treatment early due to poor response or adverse events.|
|Transfer out||Transferred to another reporting and recording unit and the treatment outcome is unknown.|
- World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world, third global report. Geneva: The Organization; 2003. Publication WHO/HTM/TB/2004.343. Available from http://www.who.int/tb/publications/who_htm_tb_2004_343/en/index.html
- Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006;194:479–85.
- World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva: The Organization; 2003. Publication WHO/CDS/2003.313. Available from http://www.who.int/tb/publications/cds_tb_2003_313/en/index.html
- Coninx R, Mathieu C, Debacker M, Mirzoev F, Ismaelov A, de Haller R, First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet. 1999;353:969–73.
- Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in 6 countries. JAMA. 2000;283:2537–45.
- Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Frequency of recurrence among MDR-TB cases ‘successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis. 2002;6:858–64.
- Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis. 2004;39:1321–8.
- van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8:560–7.
- Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318–26.
- Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474–81.
- World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis. Geneva: The Organization; 2000. Publication WHO/CDS/TB/2000.279. Available from http://www.who.int/docstore/gtb/publications/dotsplus/dotspluspilot-2000-279/english/index.htm
- Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE, Responding to market failures in tuberculosis control. Science. 2001;293:1049–51.
- Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-van Weezenbeek CS, Increasing transparency in partnerships for health—introducing the Green Light Committee. Trop Med Int Health. 2002;7:970–6.
- Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick C, Riekstina V, Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.
- Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet. 2006;367:952–5.
- World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: The Organization; 2003. Publication WHO/CDS/TB/2003.320. Available from http://www.who.int/docstore/gtb/publications/drugresistance/tb_2003_320/surveillance_guidelinespdf.pdf
- World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. Geneva: The Organization; 2005. Publication WHO/HTM/2005.349. Available from http://www.who.int/tb/publications/global_report/2005/en/index.html
- Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Management of tuberculosis: a guide for low income countries. Paris: International Union Against Tuberculosis and Lung Disease; 2000. Available from http://www.iuatld.org/pdf/en/guides_publications/management_of_tb.pdf
- World Health Organization. Guidelines for the management of drug-resistant tuberculosis. Geneva: The Organization; 1996. Publication WHO/TB/96.210. Available from http://www.who.int/docstore/gtb/publications/gmdrt/index.htm
- Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359:1980–9.
- Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I, Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis. 1995;21:1238–44.
- Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983–1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med. 1996;153:317–24.
- Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382–4.
- Tupasi TE, Gupta R, Quelapio ID, Orillaza RB, Mira NR, Mangubat NV, Feasibility and cost-effectiveness of treating patients with multidrug-resistant tuberculosis using the DOTS-Plus strategy: a cohort study in the Philippines. PLoS Med. 2006. In press.
- World Health Organization. The feasibility and efficiency of controlling MDR-TB using the DOTS-Plus strategy in the Russian Federation. Geneva: The Organization; 2005. Publication WHO/HTM/TB/2005.357C. Available from http://whqlibdoc.who.int/hq/2005/WHO_HTM_TB_2005.357_3_eng.pdf
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: The Organization; 2006. Publication WHO/HTM/2006.361. Available from http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf
- Attaran A, Barnes KI, Curtis C, d'Alessandro U, Fanello CI, Galinski MR, WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet. 2004;363:237–40.
- Gupta R, Irwin A, Raviglione MC, Kim JY. Scaling up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. Lancet. 2004;363:320–4.
- Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, Community based approaches to HIV treatment in resource poor settings. Lancet. 2001;358:404–9.
Page created: November 17, 2011
Page updated: November 17, 2011
Page reviewed: November 17, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.